The U.S. Supreme Court made it easier for shareholders to press class action securities-fraud suits, ruling that Amgen Inc. must defend against claims that it misled investors about the safety of two drugs for anemia.
The justices, voting 6-3, today said investors can sue as a group without having to first show that misinformation propped up a company’s stock price.
via Securities-Fraud Suits Backed by Supreme Court in Amgen Case – Bloomberg
